Aftins increase amyloid-β42, lower amyloid- β38, and do not alter Amyloid-β40 extracellular production in vitro: Toward a chemical model of alzheimer's disease?

Journal of Alzheimer's Disease

Volumn 35, Issue 1, 2013, Pages 107-120

  Hochard, Arnaud ^a,b   Oumata, Nassima ^a   Bettayeb, Karima ^c   Gloulou, Olfa ^d   Fant, Xavier ^b   Durieu, Emilie ^a,b   Buron, Nelly ^e   Porceddu, Mathieu ^e   Borgne Sanchez, Annie ^e   Galons, Hervé ^a,d   Flajolet, Marc ^c   Meijer, Laurent ^a  

^a Centre de Perharidy   (France)

^b STATION BIOLOGIQUE   (France)

^c ROCKEFELLER UNIVERSITY   (United States)

^d CNRS   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Aftins; Alzheimer's disease; amyloid ; mitochondria; secretase; secretase modulators

Indexed keywords

AFTIN 1; AFTIN 2; AFTIN 3; AFTIN 4; AFTIN 5; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE INHIBITOR; CYTOCHROME C; GAMMA SECRETASE INHIBITOR; OLIGOMER; PROTEIN PRECURSOR; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CHEMICAL MODEL; CONTROLLED STUDY; DOWN REGULATION; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE POTENTIAL; MITOCHONDRION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; UPREGULATION;

EID: 84876373761     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-121777     Document Type: Article

References (63)

1. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutics strategies. Cell 148, 1204-1222.
2. Selkoe DJ, Mandelkow E, Holtzman DM (2012) The Biology of Alzheimer Disease Cold Spring Harbor Press, Cold Spring Harbor, New York, pp. 511.
3. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356. Erratum in: Science 297, 2209. (Pubitemid 34790756)
4. Benilova I, Karran E, De Strooper B (2012) The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. Nat Neurosci 15, 349-357.
5. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10, 698-712.
6. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7, 656-664.
7. Lee VM, Brunden KR, Hutton M, Trojanowski JQ (2011) Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med 1, a006437.
8. Obulesu M, Venu R, Somashekhar R (2011) Tau mediated neurodegeneration: An insight into Alzheimer's disease pathology. Neurochem Res 36, 1329-1335.
9. De Strooper B, Vassar R, Golde T (2010) The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6, 99-107.
10. Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima- Kawashima M, Funamoto S, Ihara Y (2009) gamma- Secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 29, 13042-13052.
11. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C (2011) Autosomal-dominant Alzheimer's disease: A reviewand proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 3, 1.
12. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B (2010) Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J 29, 3408-3420.
13. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47, 191-199. (Pubitemid 41019251)
14. Bettayeb K, Oumata N, Zhang Y, LuoW, Bustos V, Galons H, Greengard P, Meijer L, Flajolet M (2012) A chemical route towards Alzheimer's disease? FASEB J 26, 5115-5123.
15. Findeis MA (2007) The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 116, 266-286. (Pubitemid 47451506)
16. Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, Höjrup P, Minthon L, Hansson O, Zetterberg H, Blennow K, Gobom J (2013) A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of alzheimer's disease patients and healthy controls. J Alzheimers Dis 33, 1021- 1032.
17. Blennow K, Zetterberg H, Fagan AM (2012) Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2, a006221.
18. Oumata N, Ferandin Y, Meijer L, Galons H (2009) Practical synthesis of roscovitine and CR8. Org Process Res Dev 13, 641-644.
19. Cheng S, Comer DD, Mao L, Balow GP, Pleynet D. (2004) compounds and uses thereof in modulating amyloid beta. World Intellectual Property Organization, Pub. No. WO/2004-110350.
20. Mehta PD, Pirttila T (2005) Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease. Neurodegener Dis 2, 242-245. (Pubitemid 43805907)
21. Potempska A, Mack K, Mehta P, Kim KS, Miller DL (1999) Quantification of sub-femtomole amounts of Alzheimer amyloid beta peptides. Amyloid 6, 14-21. (Pubitemid 29249931)
22. Flajolet M, He G, Heiman M, Lin A, Nairn AC, Greengard P (2007) Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I. Proc Natl Acad Sci U S A 104, 4159-4164. (Pubitemid 47181595)
23. Oumata N, Bettayeb K, Ferandin Y, Demange L, Lopez- Giral A, Goddard M-L, Myrianthopoulos V, Mikros E, Flajolet M, Greengard P, Meijer L, Galons H (2008) Roscovitine-derived, dual-specificity inhibitors of cyclindependent kinases (CDKs) and casein kinase 1 (CK1). J Med Chem 51, 5229-5242.
24. Meijer L, Raymond E (2003) Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Accounts Chem Res 36, 417-425.
25. Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, Meijer L (2008) CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 27, 5797-5807.
26. DoveyHF, JohnV, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp GM, Thorsett ED, Tung JS, Wu J, Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK, Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Little SP, Mabry TE, Miller FD, Audia JE (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76, 173-181. (Pubitemid 32044380)
27. Zhao B, Yu M, Neitzel M, Marugg J, Jagodzinski J, Lee M, Hu K, Schenk D, Yednock T, Basi G (2008) Identification of gamma-secretase inhibitor potency determinants on presenilin. J Biol Chem 283, 2927-2938.
28. Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, Yu C, Pleynet D, Digregorio PJ, Velicelebi G, Stauderman KA, Comer WT, MobleyWC, Li YM, Sisodia SS, Tanzi RE,Wagner SL (2010) Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67, 769-780.
29. Kretner B, Fukumori A, Gutsmiedl A, Page RM, Luebbers T, Galley G, Baumann K, Haass C, Steiner H (2011) Attenuated Abeta42 responses to low potency gamma-secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds. J Biol Chem 286, 15240-15251.
30. Ebke A, Luebbers T, Fukumori A, Shirotani K, Haass C, Baumann K, Steiner H (2011) Novel γ-secretase enzyme modulators directly target presenilin protein. J Biol Chem 286, 37181-37186.
31. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
32. Miners JS, Barua N, Kehoe PG, Gill S, Love S (2011) Aβ- degrading enzymes: Potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 70, 944-959.
33. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B, Wyss-Coray T (2008) The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 118, 2190-2199. (Pubitemid 351872337)
34. Ling D, Song HJ, Garza D, Neufeld TP, Salvaterra PM (2009) Abeta42-induced neurodegeneration via an age-dependent autophagic-lysosomal injury in Drosophila. PLoS One 4, e4201.
35. Jaeger PA, Pickford F, Sun CH, Lucin KM, Masliah E,Wyss- Coray T (2010) Regulation of amyloid precursor protein processing by the Beclin 1 complex. PLoS One 5, e11102.
36. Tian Y, Bustos V, Flajolet M, Greengard P (2011) A smallmolecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J 25, 1934-1942.
37. Ling D, Salvaterra PM (2011) Brain aging and Aβ1-42 neurotoxicity converge via deterioration in autophagy-lysosomal system: A conditional Drosophila model linking Alzheimer's neurodegeneration with aging. Acta Neuropathol 121, 183- 191.
38. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146-1158.
39. Nixon RA,Yang DS (2011) Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol Dis 43, 38-45.
40. Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, Schmidt SD, Wesson DW, Bandyopadhyay U, Jiang Y, Pawlik M, Peterhoff CM, Yang AJ, Wilson DA, St George-Hyslop P,WestawayD,Mathews PM,LevyE, Cuervo AM, Nixon RA (2011) Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis. Autophagy 7, 788-789.
41. Beel AJ, Sanders CR (2008) Substrate specificity of gammasecretase and other intramembrane proteases. Cell Mol Life Sci 65, 1311-1334.
42. Wakabayashi T, Craessaerts K, Bammens L, Bentahir M, Borgions F, Herdewijn P, Staes A, Timmerman E, Vandekerckhove J, Rubinstein E, Boucheix C, Gevaert K, De Strooper B (2009) Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains. Nat Cell Biol 11, 1340-1346.
43. Hur JY, Teranishi Y, Kihara T, Yamamoto NG, Inoue M, HosiaW, HashimotoM,Winblad B, Frykman S, TjernbergLO (2012) Identification of novel γ-secretase-associated proteins in detergent-resistant membranes from brain. J Biol Chem 287, 11991-12005.
44. Kukar T, MurphyMP, Eriksen JL, Sagi SA,Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, OzolsVV, Anastasiadis PZ, Das P, Fauq A,Koo EH, Golde TE (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 11, 545-550. (Pubitemid 40685978)
45. Page RM, Baumann K, Tomioka M, Pérez-Revuelta BI, Fukumori A, Jacobsen H, Flohr A, LuebbersT,OzmenL, Steiner H, Haass C (2008) Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem 283, 677-683.
46. Ohki Y, Higo T, Uemura K, Shimada N, Osawa S, Berezovska O, Yokoshima S, Fukuyama T, Tomita T, Iwatsubo T (2011) Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J 30, 4815-4824.
47. Crump CJ, Fish BA, Castro SV, Chau DM, Gertsik N, Ahn K, Stiff C, Pozdnyakov N, Bales KR, Johnson DS, LiYM(2011) Piperidine acetic acid based γ-secretase modulators directly bind to Presenilin-1. ACS Chem Neurosci 2, 705-710.
48. Czirr E, Cottrell BA, Leuchtenberger S, Kukar T, Ladd TB, Esselmann H, Paul S, Schubenel R, Torpey JW, Pietrzik CU, Golde TE, Wiltfang J, Baumann K, Koo EH, Weggen S (2008) Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. J Biol Chem 283, 17049- 17054.
49. Wolfe MS (2012) γ-secretase inhibitors and modulators for Alzheimer's disease. J Neurochem 120(Suppl 1), 89-98.
50. Oehlrich D, Berthelot DJ, Gijsen HJ (2011) γ-secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem 54, 669-698.
51. Borgegard T, Juréus A, Olsson F, Rosqvist S, Sabirsh A, Rotticci D, Paulsen K, Klintenberg R, Yan H, Waldman M, Stromberg K, Nord J, Johansson J, Regner A, Parpal S, Malinowsky D, Radesater AC, Li T, Singh R, Eriksson H, Lundkvist J (2012) First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms. J Biol Chem 87, 11810-11819.
52. Richter L, Munter LM, Ness J, Hildebrand PW, Dasari M, Unterreitmeier S, Bulic B, Beyermann M, Gust R, Reif B, Weggen S, Langosch D, Multhaup G (2010) Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc Natl Acad Sci U S A 107, 14597-14602.
53. Botev A, Munter LM, Wenzel R, Richter L, Althoff V, Ismer J, Gerling U, Weise C, Koksch B, Hildebrand PW, Bittl R, MulthaupG(2011) The amyloid precursor protein C-terminal fragment C100 occurs in monomeric and dimeric stable conformations and binds γ-secretase modulators. Biochemistry 50, 828-835.
54. Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW, Moore B, Rangachari V, Cusack B, Eriksen J, Jansen-West K, Verbeeck C, Yager D, Eckman C, Ye W, Sagi S, Cottrell BA, Torpey J, Rosenberry TL, Fauq A, Wolfe MS, Schmidt B,Walsh DM, Koo EH, Golde TE (2008) Substrate-targeting gamma-secretase modulators. Nature 453, 925-929.
55. Kukar TL, Ladd TB, Robertson P, Pintchovski SA, Moore B, Bann MA, Ren Z, Jansen-West K, Malphrus K, Eggert S, Maruyama H, Cottrell BA, Das P, Basi GS, Koo EH, Golde TE (2011) Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid β peptide length: Support for a sequential model of γ-secretase intramembrane proteolysis and regulation by the amyloid β precursor protein (APP) juxtamembrane region. J Biol Chem 286, 39804-39812.
56. Lleó A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, Frosch MP, Irizarry M, Hyman BT (2004) Nonsteroidal antiinflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 10, 1065-1066. (Pubitemid 39424866)
57. Munter LM, Voigt P, Harmeier A, Kaden D, Gottschalk KE, Weise C, Pipkorn R, Schaefer M, Langosch D, Multhaup G (2007) GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. EMBO J 26, 1702-1712. (Pubitemid 46480941)
58. Kienlen-Campard P, Tasiaux B, Van Hees J, Li M, Huysseune S, Sato T, Fei JZ, Aimoto S, Courtoy PJ, Smith SO, Constantinescu SN, Octave JN (2008) Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem 283, 7733-7744. Erratum in: J Biol Chem 283, 12680.
59. Sagi SA, Lessard CB, Winden KD, Maruyama H, Koo JC, Weggen S, Kukar TL, Golde TE, Koo EH (2011) Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein. J Biol Chem 286, 39794-39803.
60. Gong P, Vetrivel KS, Nguyen PD, Meckler X, Cheng H, Kounnas MZ, Wagner SL, Parent AT, Thinakaran G (2010) Mutation analysis of the presenilin 1 N-terminal domain reveals a broad spectrum of gamma-secretase activity toward amyloid precursor protein and other substrates. J Biol Chem 285, 38042-38052.
61. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jönsson EG, Palotie A, BehrensTW,MagnussonOT,Kong A, Thorsteinsdottir U,Watts RJ, StefanssonK(2012)Amutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99.
62. Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman-Vozari R (2011) The intranasal administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): A newrodent model to test palliative and neuroprotective agents for Parkinson's disease. Curr Pharm Des 17, 489-507.
63. Fox SH, Brotchie JM (2010) The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog Brain Res 184, 133-157.